A Deeper Dive into the REPRIEVE trial and the potential role of inflammation in residual risk

Patients living with HIV (PWH) have a 2-fold increase in the risk of developing coronary artery disease and myocardial infarction compared to those without HIV infection; this is due, in part, to a higher prevalence of traditional cardiovascular (CV) risk factors in these individuals, but also to chronic immune activation with inflammation, as well as direct viral effects1,2. Collectively, these insults result in early and aggressive atherosclerotic cardiovascular disease (ASCVD) by promoting dyslipidemia, endothelial dysfunction, atherogenesis, and thrombosis.
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Tags: Editorial Source Type: research